Evidence map›Paper›PMID 36677577›Full record

ArticleMolecules (Basel, Switzerland)2023

Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation.

Yang Hai, Ling Zuo, Meng Wang, Ruoyu Zhang, Munan Wang, Li Ren, Congwen Yang, Jianwei Wang

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Journal of pharmaceutical analysis · 2025
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yang HaiTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Ling ZuoTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Meng WangTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Ruoyu ZhangTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Munan WangTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Li RenTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Congwen YangTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Jianwei WangTraditional Chinese Medicine Key Laboratory in Chongqing for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
First People's Hospital of Chongqing · CN

Funding

the National Natural Science Foundation of China No. 81374033the National Natural Science Foundation of China No. 81973653
6 · The paper itself

Abstract

(1) Background: Icariin is the main component of the Chinese herb Epimedium. A number of studies have shown that it alleviates abnormal lipid metabolism. However, it is not clear whether and how icariin can ameliorate hepatic steatosis with polycystic ovary syndrome (PCOS). This study was designed to explore the anti-hepatosteatosis effect of icariin in rats with polycystic ovary syndrome. (2) Methods: Female Sprague Dawley(SD)rats were treated with a high-fat diet and letrozole for 21 days to make nonalcoholic fatty liver disease (NAFLD) in the polycystic ovary syndrome model. Then model rats were treated with icariin (by gavage, once daily) for 28 days. Serum hormones and biochemical variables were determined by ELISA or enzyme. RNA-sequence analysis was used to enrich related target pathways. Then, quantitative Real-time PCR (qRT-PCR) and Western blot were performed to verify target genes and proteins. (3) Results: Icariin treatment reduced excess serum levels of Testosterone (T), Estradiol (E2), Luteinizing hormone (LH), Follicle-stimulating hormone (FSH), LH/FSH ratio, insulin, triglycerides (TG), and aspartate aminotransferase (AST) in high-fat diet (HFD) and letrozole fed rats. Meanwhile, icariin ameliorated HFD and letrozole-induced fatty liver, as evidenced by a reduction in excess triglyceride accumulation, vacuolization, and Oil Red O staining area in the liver of model rats. Results of RNA-sequencing, western blotting, and qRT-PCR analyses indicated that icariin up-regulated fatty acid translocase (CD36), in mitochondria, and peroxisome proliferator-activated receptor α (PPARα) expression, which led to the enhancement of fatty acid oxidation molecules, such as cytochrome P450, family 4, subfamily a, polypeptide 3 (CYP4A3), carnitine palmitoyltransferase 1 α (CPT1α), acyl-CoA oxidase 1 (ACOX1), medium-chain acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD). Besides, icariin reduced lipid synthesis, which elicited stearoyl-Coenzyme A desaturase 1 (SCD1), fatty acid synthase (FASN), and acetyl-CoA (ACC). (4) Conclusion: Icariin showed an ameliorative effect on hepatic steatosis induced by HFD and letrozole, which was associated with improved fatty acid oxidation and reduced lipid accumulation in the liver.

Indexed as

Non-alcoholic Fatty Liver DiseasePolycystic Ovary SyndromeAnimalsDiet, High-FatFatty AcidsFemaleFlavonoidsFollicle Stimulating HormoneHumansLetrozoleLipid MetabolismLiverRatsRats, Sprague-DawleyRNATriglyceridesFatty AcidsFlavonoidsFollicle Stimulating HormoneicariinLetrozoleRNATriglyceridesfatty acid oxidationicariinliver lipid depositionnonalcoholic fatty liver diseasepolycystic ovary syndrome

Identifiers

PMID36677577
PMCPMC9861792
OpenAlexW4313574749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.